Clinical trial
D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)
NCT00143702 · University of British Columbia, Other · Completed
Key facts
| NCT number | NCT00143702 |
|---|---|
| Title | D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE) |
| Official title | Randomized, Open-Label Study of Continued Stavudine Versus Abacavir Substitution With or Without Riboflavin and Thiamine Supplementation in HIV-Infected Patients Who Have Elevated Venous Lactic Acid While on Stavudine-Based Therapy (DAVE) |
| Lead sponsor | University of British Columbia, Other |
| Collaborators | GlaxoSmithKline Industry CIHR Canadian HIV Trials Network |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Acidosis, Lactic |
| Intervention type | Drug |
| Interventions | d4T, Abacavir, Riboflavin and Thiamine (Supplementation) |
| Enrollment | 80 |
| Start date | Aug 1, 2001 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | Sep 25, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: